Bicycle Therapeutics (Bicycle Therapeutics) EBIT per Share : $-4.33 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics EBIT per Share?

Bicycle Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.61. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.33.

During the past 3 years, the average EBIT per Share Growth Rate was -25.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bicycle Therapeutics's EBIT per Share or its related term are showing as below:

BCYC' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -30.5 Med: -21.6 Max: -17
Current: -25.2

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Bicycle Therapeutics was -17.00% per year. The lowest was -30.50% per year. And the median was -21.60% per year.

BCYC's 3-Year EBIT Growth Rate is ranked worse than
78.53% of 1304 companies
in the Biotechnology industry
Industry Median: 3.6 vs BCYC: -25.20

Bicycle Therapeutics's EBIT for the three months ended in Mar. 2024 was $-26.09 Mil.

Bicycle Therapeutics EBIT per Share Historical Data

The historical data trend for Bicycle Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics EBIT per Share Chart

Bicycle Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.79

-2.68

-2.61

-3.74

-4.94

Bicycle Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-1.30	-1.40	-1.18	-1.13	-0.61

Bicycle Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bicycle Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-175.944	/	35.592
=	-4.94

Bicycle Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-26.092	/	42.560
=	-0.61

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.33

Bicycle Therapeutics (NAS:BCYC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Bicycle Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicycle Therapeutics (Bicycle Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

50BA:Germany

Address

Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS

Website

https://www.bicycletherapeutics.com

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Executives

Nigel Crockett	officer: Chief Business Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Travis Alvin Thompson	officer: Chief Accounting Officer	C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Alistair Milnes	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee	director, officer: Chief Executive Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Nicholas Keen	officer: Chief Scientific Officer	C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Michael Skynner	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Alethia Young	officer: Chief Financial Officer	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Lee Kalowski	officer: President and CFO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Santiago Arroyo	officer: Chief Development Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Dominic Smethurst	officer: Chief Medical Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham	director	1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098